-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Bristol Myers Squibb Co quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Bristol Myers Squibb Co Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$711M, a 29.7% decline year-over-year.
- Bristol Myers Squibb Co annual Deferred Income Tax Expense (Benefit) for 2023 was -$3.29B, a 20.1% decline from 2022.
- Bristol Myers Squibb Co annual Deferred Income Tax Expense (Benefit) for 2022 was -$2.74B, a 96.6% decline from 2021.
- Bristol Myers Squibb Co annual Deferred Income Tax Expense (Benefit) for 2021 was -$1.39B, a 242% decline from 2020.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)